<div is a human gene whose product lunatic Fringe (LFNG) is a member of the Fringe family of glycosyltransferases that catalyze the addition of N-acetylglucosamine (GlcNAc) to O-fucose residues on Notch receptors. This modification is a critical regulator of Notch signaling specificity and strength. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration. [1]
Lunatic Fringe (LFNG) is a member of the Fringe family of glycosyltransferases that catalyze the addition of N-acetylglucosamine (GlcNAc) to O-fucose residues on Notch receptors. This modification is a critical regulator of Notch signaling specificity and strength.
In the nervous system, LFNG plays essential roles in neurogenesis, neuronal differentiation, and synapse formation. It modulates the interaction between Notch ligands (DLL1, DLL4, JAG1, JAG2) and Notch receptors (NOTCH1-4), thereby influencing cell fate decisions during cortical development.
LFNG expression is dynamically regulated during brain development, with highest expression in the ventricular zone where neural stem cells reside. Dysregulation of LFNG-mediated Notch modification has been implicated in neurodevelopmental disorders and may contribute to neurodegeneration through effects on neural stem cell maintenance.
Neurodevelopmental Disorders:
Neurodegeneration Context:
Highest expression in fetal brain, particularly ventricular zone and subventricular zone. In adult brain, expressed in hippocampus (dentate gyrus), subventricular zone, and cerebellar Purkinje cells.
Notch pathway modulators (γ-secretase inhibitors, DLL4 blockade) may indirectly affect LFNG function. No direct LFNG-targeted therapeutics in clinical use.